TCM Biotech International Corp.

TPEX:4169 Stock Report

Market Cap: NT$3.4b

TCM Biotech International Past Earnings Performance

Past criteria checks 4/6

TCM Biotech International's earnings have been declining at an average annual rate of -1.7%, while the Biotechs industry saw earnings growing at 21.4% annually. Revenues have been growing at an average rate of 9.3% per year. TCM Biotech International's return on equity is 1.9%, and it has net margins of 2.4%.

Key information

-1.7%

Earnings growth rate

-4.4%

EPS growth rate

Biotechs Industry Growth12.2%
Revenue growth rate9.3%
Return on equity1.9%
Net Margin2.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?

Jan 31
Can You Imagine How TCM Biotech International's (GTSM:4169) Shareholders Feel About The 28% Share Price Increase?

Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend

Jan 04
Key Things To Consider Before Buying TCM Biotech International Corp. (GTSM:4169) For Its Dividend

We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt

Dec 07
We Think TCM Biotech International (GTSM:4169) Can Stay On Top Of Its Debt

Revenue & Expenses Breakdown

How TCM Biotech International makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4169 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 248342030283
31 Mar 249021934180
31 Dec 239701938077
30 Sep 239321637777
30 Jun 238951337477
31 Mar 238491635880
31 Dec 228021834182
30 Sep 227611332179
30 Jun 22720830077
31 Mar 22711528879
31 Dec 21702227680
30 Sep 21694-227083
30 Jun 21686-526486
31 Mar 217121026279
31 Dec 207372626072
30 Sep 207193425061
30 Jun 207004223950
31 Mar 206352422747
31 Dec 19569721545
30 Sep 195641020945
30 Jun 195601320446
31 Mar 195501919445
31 Dec 185402518544
30 Sep 185342218142
30 Jun 185271917740
31 Mar 185341917736
31 Dec 175411917632
30 Sep 175352217032
30 Jun 175292516331
31 Mar 175182915531
31 Dec 165063314630
30 Sep 164943214027
30 Jun 164833113425
31 Mar 164762613222
31 Dec 154702113020
30 Sep 154302512620
30 Jun 153902912221
31 Mar 153522911820
31 Dec 143142911419
30 Sep 143232911422
30 Jun 143332911425
31 Mar 143242211328

Quality Earnings: 4169 has high quality earnings.

Growing Profit Margin: 4169's current net profit margins (2.4%) are higher than last year (1.5%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4169's earnings have declined by 1.7% per year over the past 5 years.

Accelerating Growth: 4169's earnings growth over the past year (49%) exceeds its 5-year average (-1.7% per year).

Earnings vs Industry: 4169 earnings growth over the past year (49%) exceeded the Biotechs industry 8.8%.

Return on Equity

High ROE: 4169's Return on Equity (1.9%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 03:32
End of Day Share Price 2025/01/22 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TCM Biotech International Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullKGI Securities Co. Ltd.
Hsuan ChenKGI Securities Co. Ltd.